Researchers from Khyber Medical University Detail Findings in Atrial Fibrillation (Bleeding Events Associated with Rivaroxaban Therapy in Naive Patients with Nonvalvular Atrial Fibrillation: A Longitudinal Study from a Genetic Perspective with...).

Researchers from Khyber Medical University conducted a study on naive patients with atrial fibrillation treated with rivaroxaban to investigate the impact of genetic polymorphisms on plasma levels and bleeding events associated with the therapy. The study found that certain gene variants, such as ABCB1 and CYP3A5, significantly influenced the plasma concentration of rivaroxaban and were associated with an increased risk of bleeding events. This research provides valuable insights into personalized medicine approaches for patients with atrial fibrillation. [Extracted from the article]

Copyright of Hematology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)